Fig. 6: Influence of CYP2C9 in NSAID-associated adverse events.
From: Clinical impact of pharmacogenetic risk variants in a large chinese cohort
Forest plot of the ADE risk in statin users with different CYP2C9 phenotypes: (a) people who carried at least one CYP2C9 LoF alleles vs non-carriers, (b) CYP2C9 IM vs NM, and (c) CYP2C9 PM vs NM. The case number, OR, 95% CI, and P value were listed in the table. The ORs and 95% CIs were estimated using logistic regression adjusting for covariates (two-sided test). Data points represent odds ratios; error bars represent 95% confidence intervals. Significant associations are shown in red. CI = confident interval; GI = GI discomfort; IM = intermediate metabolizer; LoF = loss-of-function; NM = normal metabolizer; OR = odds ratio; PM = poor metabolizer.
